Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.
Abstract
Driver-directed therapeutics have revolutionized cancer treatment, presenting similar or better efficacy compared to traditional chemotherapy and substantially improving quality of life. Despite significant advances, targeted therapy is greatly limited by resistance acquisition, which emerges in nearly all patients receiving treatment. As a result, identifying the molecular modulators of resistance is of great interest. Recent work has implicated protein kinase C (PKC) isozymes as mediators of drug resistance in non-small cell lung cancer (NSCLC). Importantly, previous findings on PKC have implicated this family of enzymes in both tumor-promotive and tumor-suppressive biology in various tissues. Here, we review the biological role of PKC isozymes in NSCLC through extensive analysis of cell-line-based studies to better understand the rationale for PKC inhibition. PKC isoforms α, ε, η, ι, ζ upregulation has been reported in lung cancer, and overexpression correlates with worse prognosis in NSCLC patients. Most importantly, PKC isozymes have been established as mediators of resistance to tyrosine kinase inhibitors in NSCLC. Unfortunately, however, PKC-directed therapeutics have yielded unsatisfactory results, likely due to a lack of specific evaluation for PKC. To achieve satisfactory results in clinical trials, predictive biomarkers of PKC activity must be established and screened for prior to patient enrollment. Furthermore, tandem inhibition of PKC and molecular drivers may be a potential therapeutic strategy to prevent the emergence of resistance in NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of PKC can upregulate several molecular pathways, including Akt, signal transducer and activator of transcription 3 (STAT3), nuclear factor‐κB (NF‐κB) and apoptotic pathways, to regulate tumorigenesis and metastasis [112].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [112]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The binding of ligands to their receptors can activate phospholipase C, leading to the upregulation of cytosolic concentrations of the activators of PKC signaling, diacylglycerol (DAG) and Ca++ [112, 113].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“Lung cancer is the most prevalent cancer and the leading cause of cancer-related mortality worldwide, with an estimated 2,093,900 new cases and 1,761,000 deaths annually [1,2].”
BackgroundSiegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., & Nishizuka, Y. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34459-4 · Cited by 4,725 · cited 2×
“The discovery of PKC activation by tumor-promoting agent phorbol 12-myristate 13-acetate (PMA) in 1982 [28] drew attention to this family of kinases based on the plethora of cell biologic responses to PMA and other phorbol esters, warranting extensive research that implicated PKC isozymes in various pathologies, inclu…”
BackgroundZhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60735-0 · Cited by 3,908 · cited 1×
“The current clinical outcomes for lung cancer patients are far from satisfactory, and novel treatments must be developed that improve overall survival (OS) [3].”
BackgroundLung Cancer: Epidemiology, Etiology, and Prevention
Dela Cruz, C. S., Tanoue, L. T., & Matthay, R. A. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.09.001 · Cited by 2,484 · cited 1×
“NSCLC accounts for the largest subset of lung cancer cases, roughly 85%, and is further categorized into adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma [4,5].”
BackgroundCoussens, L., Parker, P. J., Rhee, L., Yang-Feng, T. L., Chen, E., Waterfield, M. D., Francke, U., & Ullrich, A. (1986) · Science · doi:10.1126/science.3755548 · Cited by 1,042
Activation of Protein Kinase C Isoforms and Its Impact on Diabetic Complications
Geraldes, P., & King, G. L. (2010) · Circulation Research · doi:10.1161/circresaha.110.217117 · Cited by 985
Structural Basis of Protein Kinase C Isoform Function
Steinberg, S. F. (2008) · Physiological Reviews · doi:10.1152/physrev.00034.2007 · Cited by 872 · cited 1×
“Biochemical analysis of PKCs revealed a highly conserved C-terminal catalytic domain, with a variable N-terminal regulatory domain (Figure 2) [26].”
BackgroundInoue, M., Kishimoto, A., Takai, Y., & Nishizuka, Y. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41010-6 · Cited by 862 · cited 1×
“Briefly, PKCs were initially discovered in 1977 by the group of Yasutomi Nishizuka [18].”
Background
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“The activation of PKC can upregulate several molecular pathways, including Akt, signal transducer and activator of transcription 3 (STAT3), nuclear factor-κB (NF-κB) and apoptotic pathways, to regulate tumorigenesis andmetastasis [112].”
BackgroundOvercoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
“Interestingly, different PKC isoforms play varying roles in tumorigenesis and metastasis (94).”
BackgroundZamanian, M. Y., Alsaab, H. O., Golmohammadi, M., Yumashev, A., Jabba, A. M., Abid, M. K., Joshi, A., Alawadi, A. H., Jafer, N. S., Kianifar, F., et al. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4030 · Cited by 105
“82”
Silnitsky, S., Rubin, S. J. S., Zerihun, M., & Qvit, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417600 · Cited by 48
“PKC signaling pathways contribute to the key cellular responses central to asthma [283–285], chronic obstructive pulmonary disease (COPD) [286], idiopathic pulmonary fibrosis (IPF) [287], acute respiratory distress syndrome (ARDS) [288,289], and lung cancer [167,290], to mention a few.”
BackgroundHe, Q., Qu, M., Bao, H., Xu, Y., Shen, T., Tan, D., Barkat, M. Q., Xu, C., Zeng, L., & Wu, X. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.03.003 · Cited by 43
NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma
Arora, R. K., Haynes, L., Kumar, M., McNeil, R., Ashkani, J., Nakoneshny, S. C., Matthews, T. W., Chandarana, S. P., Hart, R. D., Jones, S. J. M., et al. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-022-00578-8 · Cited by 41
The Role of MARCKS in Metastasis and Treatment Resistance of Solid Tumors
Chiu, C.-L., Zhao, H., Chen, C., Wu, R., & Brooks, J. D. (2022) · Cancers · doi:10.3390/cancers14194925 · Cited by 32
“MARCKS and MARCKL1 are both substrates of PKC [12], and PKC is an important signalling pathway for stemness, self-renewal, and tumorigenesis [64,65].”
BackgroundAlshehri, S. A., Wahab, S., & Almoyad, M. A. A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2252086 · Cited by 11
“Thus, PKC a has emerged as a promising therapeutic target for the treatment of cancer (Sadeghi et al., 2021).”
Exploring the prognostic significance of PKCε variants in cervical cancer
Zafar, S., Khan, K., Badshah, Y., Shahid, K., Trembley, J. H., Hafeez, A., Ashraf, N. M., Arslan, H., Shabbir, M., Afsar, T., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11236-z · Cited by 9
Targeting chaperone modifications: Innovative approaches to cancer treatment
Stewart, M., & Schisler, J. C. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107907 · Cited by 6
Chen, J., Ran, B., Chen, B., Bai, J., Jian, S., Huang, Y. C., Yang, J., Li, J., Chen, Z., Wei, Q., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13112778 · Cited by 5
“PKC ε has been implicated in regulating cell invasion and motility [40], and contributes to oncogenesis across multiple malignancies, including breast cancer [41], non-small cell lung cancer (NSCLC) [42], and prostate cancer [43].”
Wang, K., Zhang, T., Li, X., Zhang, X., Li, R., Pan, B., & Deng, J. (2024) · Gene · doi:10.1016/j.gene.2024.148321 · Cited by 4
LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells
Cho, J. H., You, Y.-M., Koo, H., Lee, D. C., Yeom, Y. I., & Park, K. C. (2022) · Cancers · doi:10.3390/cancers14092222 · Cited by 4
PhosphoDisco: A Toolkit for Co-regulated Phosphorylation Module Discovery in Phosphoproteomic Data
Schraink, T., Blumenberg, L. M., Hussey, G. A., George, S., Miller, B., Mathew, N., González-Robles, T. J., Sviderskiy, V. O., Papagiannakopoulos, T. Y., Possemato, R., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100596 · Cited by 4
Structure–activity relationship of a peptide permeation enhancer
Brunner, J., & Borchard, G. (2022) · Tissue Barriers · doi:10.1080/21688370.2022.2060692 · Cited by 3
Kiseleva, M. P., Borisova, L. M., Smirnova, G. B., Borisova, Y. A., Ланцова, А. В., Санарова, Е. В., Николаева, Л. Л., Ektova, L., & Komarova, M. V. (2022) · Research Results in Pharmacology · doi:10.3897/rrpharmacology.8.79424 · Cited by 3
“The representatives of this class: midostaurin (Li et al. 2022), enzastaurin (Sadeghi et al. 2021), lestaurtinib (Kangussu-Marcolino and Singh 2022), becatecarin (Schwandt et al. 2012), and edotecarin (Buzun et al. 2020) are undergoing clinical trials.”
BackgroundBlanchard, C., Gomeiz, A., Avery, K., Gazzah, E. E., Alsubaie, A. M., Sikaroodi, M., Chiari, Y., Ward, C., Sanchez, J., Espina, V. A., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01742-3 · Cited by 4
Biased signaling by mutant EGFR underlies dependence on PKCα in lung adenocarcinoma
Sadeghi, M., Salama, M., Chiappone, S. B., Huang, A., Resnick, A. E., Kandpal, M., Clarke, C. J., Haley, J. D., Davuluri, R. V., & Hannun, Y. A. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115026 · Cited by 4
Self-citationPKCα as a signaling gatekeeper upstream of mTORC1 in mEGFR NSCLC
Sadeghi, M., Chiappone, S. B., Salama, M. F., & Hannun, Y. A. (2025) · Advances in Biological Regulation · doi:10.1016/j.jbior.2025.101122 · Cited by 2
Self-citationGBP2 regulates lung cancer progression through STAT1 and impacts glycolysis
Xie, Q., Peng, Z., Gong, D., & Luo, H. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01932-4 · Cited by 2
“Most patients present with advanced and metastasis disease with various complications at diagnosis owe to the initial asymptomatic course, seriously threatening the lives of patients [1].”
Pulsatillic acid as a potential inhibitor of protein kinase C-alpha in non-small cell lung cancer
El-Gamal, B., Elgader, T. A., Ellatif, M. E. A., Omer, S., Saeed, M., Mohieldeen, M., Patel, A. A., Malik, A., Eid, R. A., Amanullah, M. R., et al. (2024) · Cellular and Molecular Biology · doi:10.14715/cmb/2024.70.7.7 · Cited by 2
“Several studies have reported overexpression and hyperactivation of PKCα in NSCLC tissues, correlating with advanced disease stages and poor clinical outcomes [15].”
BackgroundLinciano, P., Nasti, R., Listro, R., Amadio, M., Pascale, A., Potenza, D., Vasile, F., Minneci, M., Ann, J., Lee, J., et al. (2021) · Chirality · doi:10.1002/chir.23406 · Cited by 2
PKC in cancer: A dual role in cancer promotion and suppression
Wang, X., Duan, J., & Wang, C. (2025) · Gene Reports · doi:10.1016/j.genrep.2025.102329 · Cited by 2
Indriyanti, R. A., Ariyanto, E. F., Usman, H. A., Effendy, R. R., & Dhianawaty, D. (2026) · Pharmacognosy Journal · doi:10.5530/pj.2025.17.98 · Cited by 1
Zulkipli, N. N., Long, I., Wahab, H. A., Sasongko, T. H., Azhar, N. A., & Zakaria, R. (2024) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2024.169852
“It is overexpressed in a variety of cancer types, including non-small cell lung cancer cell lines (NSCLC) [25], a prostate cancer animal model [26], renal carcinoma cells [27], and bladder cancer [28] .”
BackgroundAn Integrated Immune-Related Bioinformatics Analysis in Lung Squamous Cell Carcinoma Patients
Zhang, Y., Du, Y., Wu, J., Chen, R., Shumei, Y., & Shang, L. (2024) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2024.3889
Investigating the pathogenic potential of PKC-eta UTR variants in cancer progression
Hussain, T., Badshah, Y., Shabbir, M., Abid, F., Khan, D., Trembley, J. H., Afsar, T., Almajwal, A. M., & Razak, S. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111283
Unravelling the modulation of tight junctions: Molecular mechanisms and permeation enhancement
Brunner, J. (2022) · Archive ouverte UNIGE (University of Geneva) · doi:10.13097/archive-ouverte/unige:161111
Blanchard, C., Gomeiz, A., Avery, K., Gazzah, E. E., Alsubaie, A. M., Sikaroodi, M., Chiari, Y., Ward, C., Sanchez, J., Espina, V. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26384561
Nargis, N., Barua, P., Mohammad, N., Haque, M. A., & Oncology Division, A. L. (2025) · Environmental Contaminants Reviews · doi:10.26480/ecr.02.2025.84.95
Molecular basis of allosteric regulation and pharmaceutical targeting of protein kinase Cβ
Cong, A. T. Q., Witter, T. L., Bruinsma, E. S., Bhattacharya, S. S., Jayaraman, S., Wyatt, S. R., Solverson, J. K., Dugan, M. B., Paluncic, J., Kuffel, M. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73413-5
“Altered PKC activity is implicated in many disease states, including cancer and neurodegenerative diseases 4,6 – 11 .”
Cell chirality in cancer: Emerging roles in malignant progression and tumor metastasis
Hu, T., Zou, J., Zhu, Z., Zhang, Z. D., Pan, Y., Lu, Y., & Chen, W. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189658
Serna, S. N., Romero, E. G., Ong, S., Golkowski, M. G., Sun, L., & Reilly, C. A. (2026) · Molecular Pharmacology · doi:10.1016/j.molpha.2026.100153
Therapeutic potential of marine sponge–derived bioactive compounds: a review
Barzkar, N., Babich, O., & Сухих, С. А. (2026) · Frontiers in Marine Science · doi:10.3389/fmars.2026.1774652
Metadata
- Authors
- Sadeghi, M. M., Salama, M. F., & Hannun, Y. A.
- Affiliations
- Department of Biochemistry, Molecular and Cellular Biology, Stony Brook University, Stony Brook, NY 11794, USA
- Mansoura University (EG)
- Stony Brook University Hospital (US)
- Corresponding author
- Hannun, Yusuf A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-05-24
- Volume
- 22
- Issue
- 11
- Pages
- 5527
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8197251
- OpenAlex
- W3164693058
- Cited by
- 31
- References
- 119
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 10 · 2023: 7 · 2022: 4 · 2021: 1
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Department of Veterans Affairs (I01 BX004621)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- protein kinase C, non-small cell lung cancer, drug resistance, tyrosine kinase inhibitors, PKC isoforms, predictive biomarkers, combination therapy, targeted therapy
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Humans, Indoles, Lung Neoplasms, Prognosis, Protein Kinase C, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Protein Isoforms, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.